MANNKIND CORP Stock Split Ratio
MANNKIND CORP (MNKD) reported Stock Split Ratio of 20.00% for the 0-month period ending 2017-03-01, per its 10-K filed 2018-02-27.
Discontinued › Notes › Equity
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2018-11-01
- 2017-03-01: Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month 20.00%; Stockholders' Equity Note, Stock Split, Conversion Ratio 20.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|---|
| 2017-03-01 | 20.00% 10-K · filed 2018-02-27 | 20.00% 10-Q · filed 2018-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |